Results of a clinical trial of Cologuard show unprecedented rates of precancer and cancer detection by a noninvasive test.
The detection rates are similar to those reported for colonoscopy. The results were published in the March 20 issue of the New England Journal of Medicine (NEJM). Cologuard was co-developed by Mayo Clinic and Exact Sciences. Cologuard, is a noninvasive sDNA test for the early detection of colorectal precancer and cancer. The Cologuard test is based on a stool sample that is analyzed for DNA signatures of precancer or cancer. The samples are easily collected, mailed from home, requires no bowel preparation, medication restriction or diet change. The clinical trial, called the DeeP-C study, included 10,000 patients and was designed to determine how well Cologuard detects precancer and cancer.
The study also compared Cologuard to the fecal immunochemical test for occult blood (FIT). The study was conducted at 90 medical centers throughout the United States and Canada. “Cologuard detection rates of early stage cancer and high-risk precancerous polyps validated in this large study were outstanding and have not been achieved by other noninvasive approaches,” says the study’s author David Ahlquist M.D., a Mayo Clinic gastroenterologist and co-inventor of the Cologuard test. “It is our hope that this accurate and user-friendly test will expand screening effectiveness and help curb colorectal cancer rates in much the same way as regular Pap smear screening has done for cervical cancer.” In the study, all patients received Cologuard, FIT and colonoscopy. Colonoscopy was the reference method. Major findings reported in the study include:
- Sensitivity of Cologuard for cancer was 92 percent overall, and 94 percent for the earliest and most curable cancer stages (stages I and II).
- Sensitivity was 69 percent for precancerous polyps at greatest risk to progress to cancer (i.e., those containing high-grade dysplasia).
- Cologuard detected significantly more cancers and significantly more precancerous polyps than did FIT.
“The most important finding of the study is the high sensitivity of Cologuard for curable stage colorectal cancer, which represents the highest sensitivity of any noninvasive test to date,” says Thomas Imperiale, M.D., a Professor of Medicine at Indiana University Medical Center in Indianapolis and a study author. “It is also significant to note that these results were achieved in a robustly conducted multicenter study.”
Colorectal cancer is often considered the most preventable, yet least prevented, cancer. Nearly 50 percent of adults age 50 and older have not been screened as recommended and, as a result, colorectal cancer has become the second-leading cause of cancer death in the United States. Colorectal cancer is highly treatable if found early, and it is preventable if the precancerous polyps at greatest risk of progressing can be detected. “Dr. Ahlquist’s work exemplifies our goal at Mayo Clinic, which is the relentless pursuit of innovation aimed to help our patients. This research will transform how we think about colorectal cancer screening going forward,” says Vijay Shah, M.D., chair of Mayo Clinic’s Division of Gastroenterology and Hepatology. Cologuard works by testing a patient’s stool for altered DNA shed during digestion. Altered DNA is known to occur within colorectal cancers and precancerous polyps.
The test also examines the stool for the presence of blood, another possible indicator of colorectal cancer. Combining the data from the stool DNA test and the blood test into a single result provides a comprehensive, powerful screening approach, which is reflected in the study results. Because of its accessibility and ease of use, researchers hope the test will increase the number of people who will choose to be screened for colorectal cancer. Screening is important because, if cancer is detected early, removing polyps during a colonoscopy can prevent the cancer. “This test has the potential to bring colon cancer screening to many patients who might otherwise go without any screening,” says Kenneth Wang, M.D., a Mayo Clinic gastroenterologist, director of the Advanced Endoscopy Group and president of the American Society for Gastrointestinal Endoscopy. “I’m hopeful that this will increase the number of patients obtaining lifesaving colonoscopy with early detection and removal of precancerous and early cancerous polyps.”
The Latest on: Colorectal Cancer Screening
via Google News
The Latest on: Colorectal Cancer Screening
- Study reveals colorectal cancer hotspots in the United Stateson June 26, 2020 at 4:13 pm
Over the last three decades, colorectal cancer survival in the United States has improved significantly. But in young people--particularly men diagnosed with colorectal cancer before age 50--incidence ...
- Early-onset colorectal cancer study in young adult men reveals 'hotspots' of death in USon June 26, 2020 at 10:58 am
Rogers said, "If young men are not already doing so, adults younger than 50 should have conversations with health care providers about early detection screening for colorectal cancer. This is ...
- A Path to Improve Colorectal Cancer Screening Outcomes: Faculty Roundtable Evaluation of Cost-Effectiveness and Utilityon June 26, 2020 at 9:47 am
Miller, MD, MPH; and A. Mark Fendrick, MD The American Journal of Managed Care® and Exact Sciences Corporation hosted a roundtable meeting to discuss the impact of colorectal cancer (CRC) screening ...
- Northwell investing $50M in cancer center, targeting diverse communitieson June 25, 2020 at 1:50 pm
Northwell Health said it plans to invest $50 million to expand cancer care in Huntington, including opening a comprehensive cancer center near Huntington Hospital. The new center would mirror the Imbe ...
- The Future of Colorectal Cancer Care is Precision Medicineon June 25, 2020 at 11:20 am
Doctors and researchers are abuzz about the field of precision medicine as it alters the landscape of cancer care. Precision ...
- More Than 10,000 Excess Cancer Deaths due to COVID-19 Delayson June 24, 2020 at 6:41 am
The National Cancer Institute predicts that more than 10,000 excess cancer deaths will occur during next 10 years because of delays in diagnosis and treatment as a result of the COVID-19 pandemic.
- Clinics, including Cedar Rapids facility, receive cancer screening grantson June 24, 2020 at 6:12 am
The Iowa Department of Public Health has been awarded $4.4 million to increase cancer screening rates at health clinics, including one in Cedar Rapids, that are caring for underserved populations, ...
- The World Market for In-Vitro Colorectal Cancer Screening Tests (2012-2027): Implications Resulting from the COVID-19 Pandemicon June 23, 2020 at 5:07 am
Vitro Colorectal Cancer Screening Tests Competitor Market Share Scenario Worldwide (in %): 2019 & 2028 Impact of COVID-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & ...
- Coronavirus Expected to Cause 10,000 More Cancer Deaths in U.S.on June 22, 2020 at 12:40 pm
The ongoing COVID-19 pandemic will likely cause at least 10,000 additional deaths from breast cancer and colorectal cancer over the next decade in the United States, according to one of the country’s ...
- Covid-Related Delays In Colorectal Cancer Screening Jeopardizes Preventive Care, Early Treatmenton June 18, 2020 at 8:06 am
PRNewswire/ -- With the COVID-19 pandemic interrupting non-urgent medical care, physicians are concerned that important gains in preventing colorectal ...
via Bing News